Norton Healthcare Home
alt
Decrease (-) Restore Default Increase (+)
Bookmark and Share
clear spacerResearch and Clinical Trials

Multiple Sclerosis Clinical Trials

Robert S. Tillett Jr., M.D., the neurologist in charge of clinical research studies for multiple sclerosis (MS) at Norton Neuroscience Institute, says these are exciting days in the treatment of this autoimmune disease. And he says MS patients in Greater Louisville are the ones who’ll benefit.

For more information about our research and clinical trials, call (502) 899-6417 or email neuroresearch@nortonhealthcare.org.   

Clinical Trials


Title: A 12-month, randomized, rater- and dose-blinded study to compare the efficacy and safety of fingolimod 0.25 mg and 0.5 mg administered orally once daily with glatiramer acetate 20 mg administered subcutaneously once daily in patients with relapsing-remitting multiple sclerosis

Sponsor: Novartis Pharmaceuticals Corp

Principal Investigator: Robert S. Tillett Jr., M.D., MSCS

Purpose: The main purpose of this study is to compare 2 doses of fingolimod (0.25 mg and 0.5 mg) with glatiramer acetate 20 mg and to evaluate the effectiveness and safety of fingolimod 0.25 mg for people with RRMS.  


Title: MS Spasticity: A Placebo-Controlled, Randomized Withdrawal Evaluation of the Efficacy and Safety of Extended Release Baclofen Capsules in Subjects with Spasticity due to Multiple Sclerosis

Sponsor: Sun Pharma Advanced Research Company (SPARC)

Principal Investigator: Robert S. Tillett Jr., M.D., MSCS

Purpose: Study of patients age 18 and older who have spasticity on a stable dose of Baclofen. Patients who qualify for this 21 week study may receive an extended release version of Baclofen to assess effectiveness. Study participants continue their disease modifying therapy and receive study related medication, lab and evaluations by an MS specialist. Compensation is provided for time and travel.


Title: MS Spasticity: A clinical evaluation of the safety of Baclofen ER Capsules (GRS) when administered once daily to subjects with spacticity due to Multiple Sclerosis (MS): An open label, long term, safety trial.

Sponsor: Sun Pharma Advanced Research Company (SPARC)

Principal Investigator: Robert S. Tillett Jr., M.D., MS certified specialist

Purpose: The purpose of this research study is to gather scientific information about the long-term safety of the investigational new drug, SPARC’s Baclofen ER Capsules (Gastro-Retentive System [GRS]) in subjects with spasticity due to MS. Extended release (ER) medication may allow you to take a medication fewer times in a single day.


Title: A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (dimethyl fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate

Sponsor: Biogen Idec Inc.

Principal Investigator: Robert S. Tillett Jr., M.D., MS certified specialist

Purpose: The purpose of the study is to find out more about the effectiveness of Tecfidera on relapse rate and quality of life in patients with MS who were previously treated with glatiramer acetate (Copaxone®).

Learn More about Multiple Sclerosis

Medical Care

Aneurysm
AVM

Brain Tumors
Epilepsy
Headache/Concussion
Movement Disorders
Multple Sclerosis
Parkinson's Disease
Pediatric Neurosurgery
Spine Care
Stroke

Locations

Norton Neurology Services

Norton Hospital Downtown
Norton Brownsboro Hospital
Norton Audubon Hospital

Neurosciences & Spine Rehabilitation Center

Norton Neurosurgeons, Neurologists, Neuro-oncologists and Pediatric Neurologists

Patients/Visitors

MyChart
Pay Your Bill
Request an Appointment
Newborns
Classes and Events
Send an eCard
Patient Stories
Places to Stay

About Us

Quality Report
Careers
Ways to Help
Community Outreach
Contact Us
(502) 629-1234

Connect with us

© 2015 Norton Healthcare
Serving Kentucky and Southern Indiana